Galapagos

Galapagos is a mid-sized biotechnology company specializing in the discovery and development of small molecule and antibody therapeutics. The company is advancing one of the largest pipelines in the biotech sector, with 6 clinical and over 50 small molecule discovery/preclinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche, and Servier, Galapagos is eligible for up to $3.3 billion in downstream milestones, as well as royalties. Galapagos has more than 800 employees, facilities in 7 countries, and its global headquarters in Mechelen, Belgium.